The vast majority of tuberculosis (TB) cases occur in resource-limited settings and despite potentially curative therapy, deaths from TB outweigh any other single bacterial pathogen. The highest rates of mortality and greatest consumption of resources reside with severe forms of TB disease, including multidrug-resistant (MDR)-TB and the neglected disease states of pediatric TB, TB meningitis and TB sepsis. Pharmacokinetic variability (suboptimal circulating drug concentrations) appears increasingly common and is particularly actionable through dose increase but has not been studied in multisite prospective cohorts or for the most severe forms of TB disease. Additionally, conventional drug-susceptibility testing for TB is crude: it uses one concentration of drug and therefore does not allow for quantification of resistance. Our preliminary work suggests quantitative susceptibility will better inform drug choice and can be adapted to fieldable molecular diagnostic platforms to ultimately deliver high-yield, individualized and actionable results for the most burdensome of TB disease. This proposal will unify established collaborators from 4 sites of diverse TB context (Tanzania, Uganda, Bangladesh, Siberia) to strengthen laboratory resources, develop personnel and build research infrastructure to study prospectively the extent and mechanisms of pharmacokinetic variability and M. tuberculosis drug-resistance (MIC) and their dual impact on treatment outcome. Over half of this ICIDR funding goes to the international collaborative sites. This proposal can contribute immediately to regional algorithms of TB treatment and will also build broad capacity for infectious disease molecular diagnostics and field epidemiology.

Public Health Relevance

The highest rates of Tuberculosis mortality and greatest consumption of resources reside with the severe forms of TB disease, including multidrug-resistant (MDR)-TB and the neglected disease states of pediatric TB, TB meningitis and TB sepsis. This proposal will build capacity to examine these severe forms of TB at diverse sites (Tanzania, Uganda, Bangladesh, Siberia) by deciphering the mechanisms of pharmacokinetic variability to anti-TB medications, effects of quantitative drug-resistance, and their dual impact on TB treatment outcome.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI115594-05
Application #
9627908
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Lacourciere, Karen A
Project Start
2015-08-15
Project End
2021-01-31
Budget Start
2019-02-01
Budget End
2021-01-31
Support Year
5
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Virginia
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Lyles, Galina; Ogarkov, Oleg; Zhdanova, Svetlana et al. (2018) Pharmacokinetics of tuberculosis drugs in HIV-infected patients from Irkutsk, Russian Federation: redefining drug activity. Eur Respir J 51:
Deshpande, Devyani; Pasipanodya, Jotam G; Mpagama, Stellah G et al. (2018) Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis. Clin Infect Dis 67:S317-S326
Deshpande, Devyani; Alffenaar, Jan-Willem C; Köser, Claudio U et al. (2018) d-Cycloserine Pharmacokinetics/Pharmacodynamics, Susceptibility, and Dosing Implications in Multidrug-resistant Tuberculosis: A Faustian Deal. Clin Infect Dis 67:S308-S316
Justine, Museveni; Yeconia, Anita; Nicodemu, Ingi et al. (2018) Pharmacokinetics of First-Line Drugs Among Children With Tuberculosis in Rural Tanzania. J Pediatric Infect Dis Soc :
van den Elsen, Simone H J; Sturkenboom, Marieke G G; Van't Boveneind-Vrubleuskaya, Natasha et al. (2018) Population Pharmacokinetic Model and Limited Sampling Strategies for Personalized Dosing of Levofloxacin in Tuberculosis Patients. Antimicrob Agents Chemother 62:
Sinkov, Viacheslav; Ogarkov, Oleg; Mokrousov, Igor et al. (2018) New epidemic cluster of pre-extensively drug resistant isolates of Mycobacterium tuberculosis Ural family emerging in Eastern Europe. BMC Genomics 19:762
van den Elsen, Simone H J; Oostenbrink, Lisette M; Heysell, Scott K et al. (2018) Systematic Review of Salivary Versus Blood Concentrations of Antituberculosis Drugs and Their Potential for Salivary Therapeutic Drug Monitoring. Ther Drug Monit 40:17-37
Heysell, Scott K; Ahmed, Shahriar; Rahman, Md Toufiq et al. (2018) Hearing loss with kanamycin treatment for multidrug-resistant tuberculosis in Bangladesh. Eur Respir J 51:
Deshpande, Devyani; Pasipanodya, Jotam G; Mpagama, Stellah G et al. (2018) Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis. Clin Infect Dis 67:S293-S302
Alffenaar, Jan-Willem C; Tiberi, Simon; Verbeeck, Roger K et al. (2017) Therapeutic Drug Monitoring in Tuberculosis: Practical Application for Physicians. Clin Infect Dis 64:104-105

Showing the most recent 10 out of 13 publications